Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Clinical studies with the Abl tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse. Through biochemical and molecular analysis of clinical material, we find that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined. In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the Abl kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance in a reconstitution experiment. In three patients, resistance was associated with progressive BCR-ABL gene amplification. These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event and suggest a strategy for identifying inhibitors of STI-571 resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast to some targeted therapies for which dominant mechanisms of resistance have been observed, such as BCR-ABL mutations that cause resistance to imatinib in chronic myeloid leukemia,22 KRASG12C-mutant cancers appear to evolve diverse mechanisms of resistance to adagrasib.”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [22]
Citations
Cites
Thompson, J. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.24.4876 · Cited by 38,993
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationStructural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Daley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
Sawyers, C. L. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401706 · Cited by 1,621
Self-citationThe Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Reversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Cited by
Items 601–700 of 1,008
Koenig, H., Holyoake, T. L., & Bhatia, R. (2007) · Blood · doi:10.1182/blood-2007-05-092056 · Cited by 108
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib
Ernst, T., Erben, P., Muller, M. C., Paschka, P., Schenk, T., Hoffmann, J., Kreil, S., Rosée, P. G. L., Hehlmann, R., & Hochhaus, A. (2008) · Haematologica · doi:10.3324/haematol.11993 · Cited by 108
“Type of BCR-ABL transcript b3a2 57 (60) b2a2 30 (32) b3a2/b2a2 4 (4) b2a3 1 (1) e1a2 2 (2) e19a2 1 (1)”
Yang, L., Wang, K., Chen, J., Jegga, A. G., Luo, H., Shi, L., Wan, C., Guo, X., Qin, S., He, G., et al. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002016 · Cited by 103
“Our study demonstrates that beside polymorphisms around the binding pocket that alter the drug efficacy via a change in the binding affinity [64,65], the off-system expression change could also determine individual variability towards the same drug, suggesting a new way of identifying biomarkers or constructing a pred…”
BackgroundABL1 fusion genes in hematological malignancies: a review
Braekeleer, E. D., Douet‐Guilbert, N., Rowe, D. W., Bown, N. P., Morel, F., Berthou, C., Férec, C., & Braekeleer, M. D. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01586.x · Cited by 119
Azam, M., Nardi, V., Shakespeare, W. C., Metcalf, C. A., Bohacek, R. S., Wang, Y., Sundaramoorthi, R., Piotr Sliz, A., Veach, D. R., Bornmann, W. G., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600001103 · Cited by 112
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias
Weisberg, E., Catley, L., Wright, R. D., Moreno, D., Banerji, L., Ray, A., Manley, P. W., Mestan, J., Fabbro, D., Jiang, J., et al. (2006) · Blood · doi:10.1182/blood-2006-06-026377 · Cited by 107
Hedgehog–Gli signaling in brain tumors: stem cells and paradevelopmental programs in cancer
Altaba, A. R. I., Stecca, B., & Sánchez, P. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00451-8 · Cited by 120
“[37] M.”
BackgroundDuesberg, P., Stindl, R., & Hehlmann, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201398998 · Cited by 106
Turning Tumors into Vaccines: Co-opting the Innate Immune System
van den Boorn, J. G., & Hartmann, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.011 · Cited by 116
Carter, B. Z., Mak, D. H. F., Schober, W. D., Cabreira-Hansen, M. D. G., Beran, M., McQueen, T. J., Chen, W., & Andreeff, M. (2005) · Blood · doi:10.1182/blood-2004-12-4704 · Cited by 110
Baccarani, M., Martinelli, G., Rosti, G., Trabacchi, E., Testoni, N., Bassi, S., Amabile, M., Soverini, S., Castagnetti, F., Cilloni, D., et al. (2004) · Blood · doi:10.1182/blood-2004-03-0826 · Cited by 106
“Time from diagnosis to enrollment, mean (range), d 50 (9-90) 51 (10-90) 43 (9-90) 50 (14-90)”
Cytogenetic and Molecular Genetic Aspects of Chronic Myeloid Leukaemia
Barnes, D., & Melo, J. V. (2002) · Acta Haematologica · doi:10.1159/000065655 · Cited by 118
“Individual point mutations within the kinase domain encoding sequences of BCR-ABL have been detected by several groups in patients who developed resistance to imatinib mesylate [”
BackgroundJabbour, E. J., Cortes, J. E., & Kantarjian, H. M. (2013) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2013.03.018 · Cited by 105
Treatment for chronic myelogenous leukemia: the long road to imatinib
Hunter, T. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31691 · Cited by 103
Beyond the Oncogene Paradigm: Understanding Complexity in Cancerogenesis
Bizzarri, M., Cucina, A., Conti, F., & D’Anselmi, F. (2008) · Acta Biotheoretica · doi:10.1007/s10441-008-9047-8 · Cited by 115
Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design
Blanc, J., Geney, R., & Menet, C. J. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520611313050008 · Cited by 111
“Moreover, mutations around the ATP pocket are reported to alter the binding properties through which the inhibitor interacts, or introduces a new steric restriction [12, 78].”
BackgroundInfluentialSonoshita, M., Itatani, Y., Kakizaki, F., Sakimura, K., Terashima, T., Katsuyama, Y., Sakai, Y., & Taketo, M. M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0595 · Cited by 102
Faes, S., Demartines, N., & Dormond, O. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1726078 · Cited by 107
MYC and therapy resistance in cancer: risks and opportunities
Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 113
Dasatinib in chronic myeloid leukemia: a review
Tsimberidou, A.-M. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3425 · Cited by 101
“…of the BCR-ABL protein, preventing imatinib from directly binding to its binding site; 16 amplifi cation of the BCR-ABL gene, leading to over-expression of BCR-ABL protein, as detected by FISH; 13,16 or over-expression of the P-glycoprotein effl ux pump, for which imatinib is the substrate.”
InfluentialHeat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents
Neckers, L., & Neckers, K. (2002) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.7.2.277 · Cited by 111
“These drug failures appear to be a result of either amplification and overexpression of Bcr-Abl or to point mutation of the protein at the site where Gleevec binds (the ATP binding site of the kinase) [59].”
Backgroundvon Bubnoff, N. C. C., Engh, R. A., Åberg, E., Sänger, J., Peschel, C., & Duyster, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2923 · Cited by 104
“Two were chosen for this study: 2HZ4 (tetrahydostaurosporine in ABL kinase; ref.”
BackgroundInfluentialSonoyama, J., Matsumura, I., Ezoe, S., Satoh, Y., Zhang, X., Kataoka, Y., Takai, E., Mizuki, M., Machii, T., Wakao, H., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111501200 · Cited by 107
von Bubnoff, N. C. C., Sandherr, M., Schlimok, G., Andreesen, R., Peschel, C., & Duyster, J. (2004) · Leukemia · doi:10.1038/sj.leu.2403600 · Cited by 103
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2)
Winger, J. A., Hantschel, O., Superti-Furga, G., & Kuriyan, J. (2009) · BMC Structural Biology · doi:10.1186/1472-6807-9-7 · Cited by 101
“However, patients in advanced stages of the disease develop resistance to imatinib treatment, due to the acquisition of mutations in the Abl kinase domain that render the protein insensitive to this inhibitor [16,17].”
Li, Z., Qiao, Y., Liu, B., Laska, E. J., Chakravarthi, P., Kulko, J. M., Bona, R., Fang, M., Hegde, U. P., Moyo, V. M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0250 · Cited by 103
To wake up cancer stem cells, or to let them sleep, that is the question
Takeishi, S., & Nakayama, K. I. (2016) · Cancer Science · doi:10.1111/cas.12958 · Cited by 102
Yang, L., Chen, J., & He, L. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000441 · Cited by 99
“c-Abl [43].”
Network-Based Approaches in Drug Discovery and Early Development
Harrold, J. M., Ramanathan, M., & Mager, D. E. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.176 · Cited by 96
“57 This mutation can be detected by assay, but such direct measures are not always available.”
BackgroundTobin, L. A., Robert, C., Rapoport, A. P., Gojo, I., Baer, M. R., Tomkinson, A. E., & Rassool, F. V. (2013) · Oncogene · doi:10.1038/onc.2012.203 · Cited by 102
Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia
Samanta, A., Perazzona, B., Chakraborty, S., Sun, X., Modi, H., Bhatia, R., Priebe, W., & Arlinghaus, R. B. (2010) · Leukemia · doi:10.1038/leu.2010.287 · Cited by 116
Prediction of Cancer Driver Mutations in Protein Kinases
Torkamani, A., & Schork, N. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5283 · Cited by 101
“This site too seems to mediate resistance to inhibitors targeting ABL T315 (25), EGFR T790 (26), KIT T670 (27), and PDGFRa (28).”
BackgroundFiskus, W. C., Pranpat, M., Balasis, M. E., Bali, P., Estrella, V. C., Kumaraswamy, S., Rao, R., Rocha, K., Herger, B. E., Lee, F. Y., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0980 · Cited by 102
Crystal Structure of the T315I Mutant of Abl Kinase
Zhou, T., Parillon, L., Li, F., Wang, Y., Keats, J. A., Lamore, S. D., Xu, Q., Shakespeare, W. C., Dalgarno, D. C., & Zhu, X. (2007) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2007.00556.x · Cited by 110
Yokota, A., Kimura, S. H., Masuda, S., Ashihara, E., Kuroda, J., Sato, K., Kamitsuji, Y., Kawata, E., Deguchi, Y., Urasaki, Y., et al. (2006) · Blood · doi:10.1182/blood-2006-03-013250 · Cited by 104
“Mice were divided into 6 groups as follows: (1) untreated mice (vehicle only); (2) mice treated with 400 mg imatinib mesylate/kg per day; (3) mice treated with 6 mg INNO-406/kg per day; (4) mice treated with 20 mg INNO-406/kg per day; (5) mice treated with 60 mg INNO-406/kg per day; and (6) mice treated with 120 mg IN…”
MethodMarktel, S., Marín, D., Foot, N. J., Szydlo, R., Bua, M., Karadimitris, A., Melo, V. A. S. D., Kotzampaltiris, P., Dazzi, F., Rahemtulla, A., et al. (2003) · PubMed · Cited by 102
Metabolomics Applications in Precision Medicine: An Oncological Perspective
Puchades‐Carrasco, L., & Pineda‐Lucena, A. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026617666170707120034 · Cited by 105
“Human CML cell lines with loss of imatinib sensitivity display increased glycolytic rate and phosphocoline levels, metabolic alterations that are considered to sustain cell proliferation in these conditions [96].”
BackgroundInfluentialThe rise and fall of gatekeeper mutations? The BCR‐ABL1 T315I paradigm
Gibbons, D. L., Pricl, S., Kantarjian, H. M., Cortes, J. E., & Quintás‐Cardama, A. (2011) · Cancer · doi:10.1002/cncr.26225 · Cited by 112
“Second, such mutation also causes steric hindrance between the large hydrophobic isoleucine residue and any of the 3 TKIs, thus blocking the access of the latter to the hydrophobic pocket in the proximity of Thr315.”
BackgroundInfluentialHaller, F., Detken, S., Schulten, H.-J., Happel, N., Gunawan, B., Kuhlgatz, J., & FÜZESI, L. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9228-0 · Cited by 101
Dasatinib: a new step in molecular target therapy
Olivieri, A., & Manzione, L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm223 · Cited by 101
“Alternative mechanisms include overexpression of the P-glycoprotein efflux pump, dysregulation of src family of tyrosine kinases (SFK) activity and activation of other pathways [11, 12].”
BackgroundLu, Z., Jin, Y., Qiu, L., Lai, Y., & Pan, J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.09.006 · Cited by 103
“Although resistance to imatinib may involve many different mechanism [8–11], acquired secondary mutations in the kinase domain of Bcr–Abl are believed to be the predominant mechanisms underlying the resistance [11,12].”
BackgroundMizutani, T., Kondo, T., Darmanin, S., Tsuda, M., Tanaka, S., Tobiume, M., Asaka, M., & Ohba, Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0548 · Cited by 103
“encouraged us to examine whether the expression level of BCR-ABL was in any way related to drug resistance, as has already been proposed (28).”
BackgroundSun, H., Li, Y., Tian, S., Wang, J., & Hou, T. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003729 · Cited by 99
“survive by means of activating other signaling pathways [12–16], regulating the expression level of the associated genes or gene products [17–19], or more directly, hindering the drugs binding [20,21], enhancing the substrates binding [22], or re-activating the target [23] with acquired secondary mutations in the drug…”
BackgroundSustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate
Labropoulos, S. V., Fletcher, J. A., Oliveira, A. M., Papadopoulos, S., & Razis, E. D. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200504000-00014 · Cited by 100
Zhang, H., Trachootham, D., Lu, W., Carew, J. S., Giles, F. J., Keating, M. J., Arlinghaus, R. B., & Huang, P. (2008) · Leukemia · doi:10.1038/leu.2008.74 · Cited by 100
Tanaka, H., & Yao, M.-C. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2591 · Cited by 101
“Increased copy number of the breakpoint cluster region ( BCR )– ABL1 fusion gene is associated with resistance to the drug that inhibits its product because the overproduction of BCR–ABL1 overcomes the dru”
BackgroundRosée, P. G. L., Johnson, K. J., Corbin, A. S., Stoffregen, E. P., Mosesón, E. M., Willis, S. G., Mauro, M., Melo, J. V., Deininger, M. W., & Druker, B. J. (2003) · Blood · doi:10.1182/blood-2003-04-1074 · Cited by 107
Defining and Managing Imatinib Resistance
Mauro, M. J. (2006) · Hematology · doi:10.1182/asheducation-2006.1.219 · Cited by 100
Zonder, J. A., Pemberton, P., Brandt, H., Mohamed, A. N., & Schiffer, C. A. (2003) · PubMed · Cited by 106
Rosée, P. G. L., O'Dwyer, M. E., & Druker, B. J. (2002) · Leukemia · doi:10.1038/sj.leu.2402555 · Cited by 104
Monitoring treatment of chronic myeloid leukemia
Baccarani, M., Pane, F., & Saglio, G. N. (2008) · Haematologica · doi:10.3324/haematol.12588 · Cited by 99
le Coutre, P. D., Giles, F. J., Hochhaus, A., Apperley, J. F., Ossenkoppele, G. J., Blakesley, R. E., Shou, Y., Gallagher, N. J., Baccarani, M., Cortes, J. E., et al. (2011) · Leukemia · doi:10.1038/leu.2011.323 · Cited by 99
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia
Zhu, J., Zhou, L., Wu, G., Koenig, H., Lin, X., Li, G., Qiu, X., Chen, C., Hu, C., Goldblatt, E. M., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201760 · Cited by 106
“Given the unstable genomic background of cancer cells, tyrosine kinases are prone to secondary mutations, leading to drug-resistance issues (Deininger et al, 2005; Gorre et al, 2001; Nardi et al, 2004).”
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)
Komarova, N. L., Burger, J. A., & Wodarz, D. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409362111 · Cited by 98
“The only circumstance under which we can expect the presence of resistance with less certainty is if assumption (iii) is violated; that is, if mutant generation requires more than one mutational hit (for example, if gene amplification is required for resistance) (25).”
BackgroundHochhaus, A., Saglio, G. N., Larson, R. A., Kim, D., Étienne, G., Rosti, G., Souza, C. A. D., Kurokawa, M., Kalaycio, M. E., Hoenekopp, A., et al. (2013) · Blood · doi:10.1182/blood-2012-04-423418 · Cited by 98
Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies
Jang, S., & Atkins, M. B. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.197 · Cited by 103
Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
Ou, X., Gao, G., Habaz, I. A., & Wang, Y. (2024) · MedComm · doi:10.1002/mco2.694 · Cited by 115
“52 Molecularly, the hydroxyl group of threonine 315 can form a hydrogen bond with imatinib upon binding, while the side chain located at position 315 also regulates the steric interaction, governing the inhibitor’s binding to hydrophobic regions neighboring the ATP-binding pocket.”
BackgroundPocaly, M., Lagarde, V., Étienne, G., Ribeil, J., Claverol, S., Bonneu, M., Moreau‐Gaudry, F., Guyonnet‐Dupérat, V., Hermine, O., Melo, J. V., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404463 · Cited by 98
Yeh, H. H., Ogawa, K., Balatoni, J., Mukhapadhyay, U., Pal, A., González-Lepera, C., Shavrin, A., Soghomonyan, S., Flores, L. G., Young, D. P., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010744108 · Cited by 100
“This mechanism is analogous to that resulting from the T315L mutation in Bcr-Abl, which leads to imatinib resistance (57).”
BackgroundWhat Makes Tumors Multidrug Resistant?
Borst, P., Jonkers, J., & Rottenberg, S. (2007) · Cell Cycle · doi:10.4161/cc.6.22.4936 · Cited by 106
Chen, R., Gandhi, V. V., & Plunkett, W. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1216 · Cited by 98
Hsp90 Inhibitors in the Clinic
Pacey, S., Banerj, U., Judson, I. R., & Workman, P. (2005) · Springer eBooks · doi:10.1007/3-540-29717-0_14 · Cited by 109
“Early optimism has been blunted by tumours acquiring resistance to these new agents, for example by further mutations in the kinase domain giving rise to imatinib resistance (Chen et al. 2004; Gorre et al. 2001; Shah et al. 2002).”
BackgroundHickman, J. A. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00266-0 · Cited by 98
Cardiotoxicity of the new cancer therapeutics – mechanisms of, and approaches to, the problem
Force, T. L., & Kerkelä, R. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.05.011 · Cited by 108
Polypharmacology in Precision Oncology: Current Applications and Future Prospects
Antolín, A. A., Workman, P., Mestres, J., & Al‐Lazikani, B. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160923115828 · Cited by 111
“Moreover, the subsequent identification of BCR-ABL second mutations and also amplifications among patients that responded to imatinib initially but relapsed afterwards provides definitive clinical proof that imatinib’s efficacy in CML is driven through BCR-ABL inhibition [42].”
BackgroundLipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo
Jyotsana, N., Sharma, A. K., Chaturvedi, A., Budida, R., Scherr, M., Kuchenbauer, F. C., Lindner, R. M., Noyan, F., Sühs, K., Stangel, M., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03713-y · Cited by 101
Yamamoto‐Sugitani, M., Kuroda, J., Ashihara, E., Nagoshi, H., Kobayashi, T., Matsumoto, Y., Sasaki, N., Shimura, Y., Kiyota, M., Nakayama, R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111138108 · Cited by 97
Catalano, A., Rodilossi, S., Rippo, M. R., Caprari, P., & Procopio, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406696200 · Cited by 98
Smac mimetics: implications for enhancement of targeted therapies in leukemia
Weisberg, E., Ray, A., Barrett, R., Nelson, E., Christie, A. L., Porter, D., Straub, C., Zawel, L., Daley, J. F., Lazo-Kallanian, S., et al. (2010) · Leukemia · doi:10.1038/leu.2010.212 · Cited by 93
Tarumoto, T., Nagai, T., Ohmine, K., Miyoshi, T., Nakamura, M., Kondo, T., Mitsugi, K., Nakano, S., Muroi, K., Komatsu, N., et al. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.01.007 · Cited by 99
Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition
Li, L., Dai, H., Ye, M., Wang, S., Xiao, X.-J., Zheng, J., Chen, H.-Y., Luo, Y., & Liu, J. (2012) · Cancer Cell International · doi:10.1186/1475-2867-12-49 · Cited by 97
“However, many patients report developing resistance to Glivec due to mutations in the Abl kinase domain [1,2].”
BackgroundSystems-pharmacology dissection of a drug synergy in imatinib-resistant CML
Winter, G. E., Rix, U., Carlson, S. M., Gleixner, K. V., Grebien, F., Gridling, M., Müller, A. C., Breitwieser, F. P., Bilban, M., Colinge, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1085 · Cited by 97
Discovery of Drug-Resistant and Drug-Sensitizing Mutations in the Oncogenic PI3K Isoform p110α
Zunder, E. R., Knight, Z. A., Houseman, B. T., Apsel, B., & Shokat, K. M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.014 · Cited by 95
“…of resistance to protein kinase inhibitors in cancer therapy is point mutation of the target kinase that blocks drug binding (Daub et al., 2004; Gorre et al., 2001; Mahon et al., 2000; Shah et al., 2002; Shah and Sawyers, 2003), and mutation at one position in particular is frequently observed…”
Turning liabilities into opportunities: Off-target based drug repurposing in cancer
Palve, V. C., Liao, Y., Rix, L. L. R., & Rix, U. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.003 · Cited by 103
A common phosphotyrosine signature for the Bcr-Abl kinase
Goss, V. L., Lee, K. A., Moritz, A., Nardone, J., Spek, E. J., MacNeill, J., Rush, A. J., Comb, M. J., & Polakiewicz, R. D. (2006) · Blood · doi:10.1182/blood-2005-08-3399 · Cited by 107
“1,2 This disease is characterized by the presence of the t(9;22)(q34;q11) Philadelphia chromosome (Ph) translocation3 arising from fusion of a portion of the breakpoint cluster region (BCR) gene with the Abl tyrosine kinase, leading to constitutive tyrosine kinase activity and increased phosphorylation of downstream t…”
Wang, Y., Chia, Y. L., Nedelman, J. R., SCHRAN, H. F., Mahon, F., & Molimard, M. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181b2c8cf · Cited by 96
Parker, W. T., Lawrence, R. M., Ho, M., Irwin, D. L., Scott, H. S., Hughes, T. P., & Branford, S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.0934 · Cited by 95
A review of erlotinib and its clinical use
Tang, P. A., Tsao, M., & Moore, M. J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.2.177 · Cited by 100
“This is analogous to the ‘gatekeeper mutation’ that confers resistance to imatinib for chronic myelogenous leukaemia [100].”
BackgroundSurvival of lung adenocarcinoma patients with malignant pleural effusion
Wu, S., Yu, C., Tsai, M., Liao, W., Yang, C.-H., Jan, I., Yang, P., & Shih, J. (2012) · European Respiratory Journal · doi:10.1183/09031936.00069812 · Cited by 108
Schulenburg, A., Blatt, K., Cerny‐Reiterer, S., Sadovnik, I., Herrmann, H., Marian, B., Grunt, T. W., Zielinski, C. C., & Valent, P. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0113-9 · Cited by 98
“The best studied model is CML, where multiple mutations in the BCR/ABL kinase domains have been identified in Imatinib-treated patients [326-328].”
BackgroundSingh, A. P., Glennon, M. S., Umbarkar, P., Gupte, M., Galindo, C. L., Zhang, Q., Force, T. L., Becker, J. R., & Lal, H. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz006 · Cited by 96
Neurofibromin and suppression of tumorigenesis: beyond the GAP
Mo, J., Moye, S. L., McKay, R. M., & Le, L. Q. (2022) · Oncogene · doi:10.1038/s41388-021-02156-y · Cited by 100
“Resistance to MEK kinase inhibitor treatment of these remaining cells with stem-like properties could be due to development of gatekeeper mutations [152, 153], by activation of another bypass pathway to restore signaling downstream of the drug [154], or by switching lineages from a MEK-dependent cell type to a MEK-ind…”
BackgroundFischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00082-6 · Cited by 107
Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors
Angstreich, G. R., Matsui, W. H., Huff, C. A., Vala, M. S., Barber, J., Hawkins, A. L., Griffin, C. A., Smith, B. D., & Jones, R. J. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05606.x · Cited by 95
“Clinical resistance to imatinib may result from BCR-ABL gene amplification or mutations (Gorre et al, 2001).”
BackgroundRadujkovic, A., Schad, M., Topaly, J., Veldwijk, M. R., Laufs, S., Schultheis, B. S., Jauch, A. T., Melo, J. V., Früehauf, S., & Zeller, W. J. (2005) · Leukemia · doi:10.1038/sj.leu.2403764 · Cited by 99
“Reported mechanisms of resistance to imatinib are overexpression of BCR-ABL transcripts, genomic amplification of the BCR-ABL fusion gene, point mutations of the tyrosine kinase domain and occurrence of additional chromosomal aberrations resulting in clonal evolution”
BackgroundDesigning bisubstrate analog inhibitors for protein kinases
Parang, K., & Cole, P. A. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00184-5 · Cited by 110
“Gorre et al. (2001) showed that ‘‘acquired’’ resistance to STI-571 is often associated with reactivation of the tyrosine kinase activity of the BCR-ABL oncoprotein.”
BackgroundRosée, P. G. L., Johnson, K. J., O'Dwyer, M. E., & Druker, B. J. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00836-6 · Cited by 97
“Several mechanisms of resistance have been reported, including point mutations within the abl kinase domain [9,10], gene amplification of the Bcr-Abl locus, and BcrAbl mRNA overexpression [11–13], all leading to reactivation of the Bcr-Abl kinase.”
BackgroundFontana, D., Ceccon, M., Gambacorti-Passerini, C. B., & Mologni, L. (2015) · Cancer Medicine · doi:10.1002/cam4.413 · Cited by 98
“From a molecular point of view, ALK L1196M corresponds to the highly TKI resistant BCR-ABL T315I [32], c-KIT T670I [33], and EGFR T790M [34, 35] mutations.”
BackgroundMayerhofer, M., Gleixner, K. V., Mayerhofer, J., Hoermann, G., Jaeger, E., Aichberger, K. J., Ott, R. G., Greish, K. F., Nakamura, H., Derdak, S. V., et al. (2007) · Blood · doi:10.1182/blood-2006-11-055723 · Cited by 96
Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia
Quintás‐Cardama, A., & Cortes, J. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0117 · Cited by 102
Wakai, T., Kanda, T., Hirota, S., Ohashi, A., Shirai, Y., & Hatakeyama, K. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601819 · Cited by 94
“In CML, resistance to imatinib is conferred by a similar mechanism involving ABL kinase; this was shown clinically and in vitro (Gorre et al, 2001).”
BackgroundTreatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution
Venkatesan, S., Swanton, C., Taylor, B. S., & Costello, J. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026617 · Cited by 106
“2000; Weisberg and Griffin 2000) and ABL kinase domain mutations (Gorre et al. 2001; Branford et al. 2003), were identified early on in (pre-) clinical studies.”
BackgroundBartholomeusz, G. A., Talpaz, M., Kapuria, V., Kong, L. Y., Wang, S., Estrov, Z. E., Priebe, W., Wu, J. Y., & Donato, N. J. (2007) · Blood · doi:10.1182/blood-2006-02-005579 · Cited by 97
Drug resistance in mutant FLT3-positive AML
Weisberg, E., Sattler, M., Ray, A., & Griffin, J. D. (2010) · Oncogene · doi:10.1038/onc.2010.273 · Cited by 93
“Such point mutations result in amino-acid changes in the catalytic domain of the BCRABL protein that reduce the ability of imatinib to bind and inhibit the tyrosine kinase activity of the enzyme (Gorre et al., 2001).”
Shifting paradigms: the seeds of oncogene addiction
Sawyers, C. L. (2009) · Nature Medicine · doi:10.1038/nm1009-1158 · Cited by 93
Self-citationAcute leukemia: A pediatric perspective
Downing, J. R., & Shannon, K. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00211-8 · Cited by 112
Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells
Tipping, A. J., Mahon, F., Lagarde, V., Goldman, J. M., & Melo, J. V. (2001) · Blood · doi:10.1182/blood.v98.13.3864 · Cited by 102
Molecular Genetics of Acute Lymphoblastic Leukemia
Teitell, M. A., & Pandolfi, P. P. (2008) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092227 · Cited by 114
Aichberger, K. J., Mayerhofer, M., Krauth, M.-T., Vales, A., Kondo, R., Derdak, S., Pickl, W. F., Selzer, E., Deininger, M., Druker, B. J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0972 · Cited by 91
Toyokawa, G., & Seto, T. (2015) · Oncology Research and Treatment · doi:10.1159/000430852 · Cited by 99
Metadata
- Authors
- Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Department of Pathology, and
- Department of Medicine,
- Corresponding author
- Sawyers, Charles L.
- Venue
- Science
- Published
- 2001-08-03
- Volume
- 293
- Issue
- 5531
- Pages
- 876-880
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1999614615
- Cited by
- 3,104
- References
- 26
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 45 · 2023: 64 · 2022: 44 · 2021: 60 · 2020: 71 · 2019: 76 · 2018: 68 · 2017: 84 · 2016: 96 · 2015: 106 · 2014: 141 · 2013: 169 · 2012: 162
- FWCI
- 85.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM-07185, T32GM007185)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- imatinib, BCR-ABL, chronic myeloid leukemia, drug resistance, Abl tyrosine kinase, BCR-ABL mutations, relapse
- MeSH terms
- Imatinib Mesylate, Amino Acid Sequence, Antineoplastic Agents, Base Sequence, Benzamides, Blast Crisis, Cell Line, Gene Amplification, Humans, Hydrogen Bonding, Molecular Sequence Data, Philadelphia Chromosome, Phosphorylation, Piperazines, Proto-Oncogene Proteins, Pyrimidines, Recurrence, Signal Transduction, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Genes, abl, Proto-Oncogene Proteins c-abl, Point Mutation, Protein Structure, Tertiary, Drug Resistance, Neoplasm, Amino Acid Substitution, Proto-Oncogene Proteins c-crk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.